跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 14,039 条关于
“NaV1.8 sodium channel”
全部
14,039
临床试验
11,696
药物
1,322
机构
51
资讯
970
去年
Vertex Pharmaceuticals Discontinues VX-993 Development After Phase 2 Failure in Acute Pain
2个月前
Latigo Biotherapeutics Files for IPO as Non-Opioid Pain Drug LTG-001 Advances to Late-Stage Testing
去年
Vertex Pharmaceuticals Announces FDA Approval of JOURNAVX™ (suzetrigine) for Acute Pain
2年前
Vertex's Non-Opioid Pain Drug VX-548 Achieves Positive Phase 3 Results
去年
FDA Grants Fast Track Status to Latigo's Novel Non-Opioid Pain Treatment LTG-001
2年前
FDA Accepts Vertex's Suzetrigine NDA with Priority Review for Acute Pain
去年
Vertex's Non-Opioid Suzetrigine Shows Promise in Phase 3 Acute Pain Trials
2年前
Novel NaV1.8 Inhibitors Lead Wave of Non-Opioid Pain Treatments as Industry Tackles Opioid Crisis
去年
FDA Gears Up for Critical Decisions on Alzheimer's, Breast Cancer, and Neurological Therapies in Early 2025
8个月前
FDA Approves First-in-Class Non-Opioid Journavx for Acute Pain, Marking 20-Year Breakthrough
第 1 页,共 97 页
上一页
下一页